Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Lenalidomide in Diffuse Large B-Cell Lymphoma: NCT06516978 Clinical Landscape Report 2026
15 October 2026
NCT06516978 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
JWCAR201 in Diffuse Large B-Cell Lymphoma: NCT06517004 Clinical Landscape Report 2026
15 October 2026
NCT06517004 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
68Ga-C1 in Renal Cell Carcinoma: NCT06519760 Clinical Landscape Report 2026
15 October 2026
NCT06519760 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Selinexor in Diffuse Large B-Cell Lymphoma: NCT06517511 Clinical Landscape Report 2026
15 October 2026
NCT06517511 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lenalidomide in T-cell/histiocyte rich large B-cell lymphoma: NCT06521255 Clinical Landscape Report 2026
15 October 2026
NCT06521255 clinical landscape for T-cell/histiocyte rich large B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and developmen…
9 min read
FDA018 Antibody Drug Conjugate(Shanghai Fudan Zhangjiang Bio Pharmaceutical) in Triple Negative Breast Cancer: NCT06519370 Clinical Landscape Report 2026
15 October 2026
NCT06519370 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sintilimab in Advanced Renal Cell Carcinoma: NCT06523049 Clinical Landscape Report 2026
15 October 2026
NCT06523049 clinical landscape for Advanced Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cobolimab in Hodgkin's Lymphoma: NCT06521567 Clinical Landscape Report 2026
15 October 2026
NCT06521567 clinical landscape for Hodgkin's Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lenalidomide in Diffuse Large B-Cell Lymphoma: NCT06522555 Clinical Landscape Report 2026
15 October 2026
NCT06522555 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
UB-VV111 in Chronic Lymphocytic Leukemia: NCT06528301 Clinical Landscape Report 2026
15 October 2026
NCT06528301 clinical landscape for Chronic Lymphocytic Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Targeting Survivin DC Cells (Tricision) in Glioblastoma Multiforme: NCT06524063 Clinical Landscape Report 2026
15 October 2026
NCT06524063 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ranolazine in Muscle Cramp: NCT06527222 Clinical Landscape Report 2026
15 October 2026
NCT06527222 clinical landscape for Muscle Cramp: endpoints, sponsor, phase, geography, readouts, asset context and development white space.